EMA Application withdrawn: Qinprezo (vosaroxin) — Sunesis Europe Ltd

View source ↗

Summary

European EMA withdrawn the application for Qinprezo (vosaroxin) for acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Qinprezo (vosaroxin)

Snippet

Status: Application withdrawn. Therapeutic area: Leukemia, Myeloid, Acute. MAH: Sunesis Europe Ltd. Decision date: 19/05/2017